Literature DB >> 21281218

Treatment and predictors of outcome in dogs with immune-mediated thrombocytopenia.

Shana K O'Marra1, Armelle M Delaforcade, Scott P Shaw.   

Abstract

OBJECTIVE: To characterize the clinical course of disease and identify prognostic indicators for immune-mediated thrombocytopenia in dogs.
DESIGN: Retrospective cohort study. ANIMALS: 73 dogs treated for immune-mediated thrombocytopenia at the Foster Hospital for Small Animals at the Tufts Cummings School of Veterinary Medicine and the Tufts Veterinary Emergency Treatment and Specialties Hospital. PROCEDURES: Medical records from the period of January 2002 through June 2008 were reviewed to identify dogs with a diagnosis of immune-mediated thrombocytopenia. Data collected included signalment, clinical signs, results of initial diagnostic tests, treatment, complications, and survival duration.
RESULTS: Dog ages ranged from 5 months to 15 years (median, 8.1 years). Cocker Spaniels were overrepresented, compared with their distribution in the entire hospital population during the same period. Sixty-one of the 73 (84%) dogs survived to discharge. Seven (11 %) of those dogs were lost to follow-up. Five of the remaining 54 (9%) dogs had a relapse of the disease. The presence of melena or high BUN concentration at admission to the hospital was significantly correlated with a decreased probability of survival. CONCLUSIONS AND CLINICAL RELEVANCE: Immune-mediated thrombocytopenia is a serious yet treatable disease, which may have a lower rate of recurrence than previously reported. The presence of melena or high BUN concentration in the study suggested a poor prognosis for affected dogs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281218     DOI: 10.2460/javma.238.3.346

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  17 in total

1.  Evaluation of a DLA-79 allele associated with multiple immune-mediated diseases in dogs.

Authors:  Steven G Friedenberg; Greg Buhrman; Lhoucine Chdid; Natasha J Olby; Thierry Olivry; Julien Guillaumin; Theresa O'Toole; Robert Goggs; Lorna J Kennedy; Robert B Rose; Kathryn M Meurs
Journal:  Immunogenetics       Date:  2015-12-28       Impact factor: 2.846

2.  Outcome based on treatment protocol in patients with primary canine immune-mediated thrombocytopenia: 46 cases (2000-2013).

Authors:  Margaret Ann Scuderi; Elizabeth Snead; Susan Mehain; Cheryl Waldner; Tasha Epp
Journal:  Can Vet J       Date:  2016-05       Impact factor: 1.008

3.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

4.  Application of vincristine-loaded platelet therapy in three dogs with refractory immune-mediated thrombocytopenia.

Authors:  Hyung-Jin Park; Ja-Won Kim; Kun-Ho Song; Kyoung-Won Seo
Journal:  J Vet Sci       Date:  2014-09-30       Impact factor: 1.672

5.  Efficacy of intravenous administration of combined acid suppressants in healthy dogs.

Authors:  M K Tolbert; A Odunayo; R S Howell; E E Peters; A Reed
Journal:  J Vet Intern Med       Date:  2015-02-25       Impact factor: 3.333

6.  Development and implementation of a novel immune thrombocytopenia bleeding score for dogs.

Authors:  Kelly M Makielski; Marjory B Brooks; Chong Wang; Jonah N Cullen; Annette M O'Connor; Dana N LeVine
Journal:  J Vet Intern Med       Date:  2018-04-21       Impact factor: 3.333

7.  Application of therapeutic plasma exchange in dogs with immune-mediated thrombocytopenia.

Authors:  Lucy Kopecny; Carrie A Palm; Sean Naylor; John Kirby; Larry D Cowgill
Journal:  J Vet Intern Med       Date:  2020-06-19       Impact factor: 3.333

Review 8.  Oral cyclosporine treatment in dogs: a review of the literature.

Authors:  T M Archer; D M Boothe; V C Langston; C L Fellman; K V Lunsford; A J Mackin
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

9.  Platelet volume and plateletcrit in dogs with presumed primary immune-mediated thrombocytopenia.

Authors:  D Schwartz; L Sharkey; P J Armstrong; C Knudson; J Kelley
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

10.  Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.

Authors:  Barbara Kohn; Gürkan Bal; Aleksandra Chirek; Sina Rehbein; Abdulgabar Salama
Journal:  BMC Vet Res       Date:  2016-06-10       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.